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ABSTRACT
Objectives: To estimate (i) the incidence of occult uterine leiomyosarcoma (LMS) in patients operated on for presumed 
myomas, and (ii) the proportion of occult LMS to preoperatively diagnosed LMS in a tertiary center.
Material and methods: An Institutional Review Board-approved retrospective cohort study was performed. The electronic 
database of 30,476 patients was searched for women who had undergone surgery due to presumed myomas (N = 2675) as 
well as those with uterine LMS recognized via histology (N = 10) between January 2010 and December 2016.
Results: Six of the 2675 treated women had occult LMS (incidence 1:446; 0.002; CI 0.0–0.013), and one underwent power 
morcellation (incidence 1:951; 0.001; CI 0.0–0.006). Parallel searching revealed that 6 of the 10 cases (60%) with uterine LMS 
recognized via histology were diagnosed postoperatively, whereas 4 of the 10 (40%) were diagnosed preoperatively. The 
incidence of LMS morcellation during laparoscopy was 1:951 and, when all MIS cases were included, 1:1178. The patient 
who underwent LMS morcellation was operated in the general surgery ward 5 years after laparoscopy (omental recurrence).
Conclusions: These results are similar to the first and recent conservative FDA estimations, but two-times lower for 
procedures with laparoscopic morcellation and all MIS procedures than for abdominal. Because above half of LMS may 
be recognized after surgery, the risk of occult LMS and the delay of targeted surgical treatment should be included in all 
informed consent forms for conservative management of presumed myomas without histology.
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INTRODUCTION 
After a well-educated injured patient pointed out the 
underestimation of occult malignancy risk and questioned 
the safety of power morcellation, a polarizing debate [1–3] 
began which resulted in the first estimation of the prevalence 
of occult LMS by the Food and Drug Administration (FDA) [4] 
and a significant restriction in the use of morcellators in 
clinical practice in the United States. The prevalence of unex-
pected LMS varies from 1:495 to 1:1100, by FDA estimations, 
to 1:8000, depending on the analytical method used [5, 6]. 
Many reports selectively focus on specific laparoscopic pro-
cedures, without showing the prevalence of occult malignan-
cy in other myoma surgery procedures, nor determining the 
proportion of occult LMS to all cases of recognized LMS [7].
The main purposes of this study were to estimate (i) 
the incidence of occult uterine LMS in patients operated 
on for presumed fibroids, and (ii) the proportion of oc-
cult LMS diagnosed preoperatively. The secondary aims 
were to determine the incidence of uterine LMS during 
minimally invasive surgery (MIS) techniques, including 
high-power morcellation. Moreover, the incidence of oc-
cult LMS was analyzed in relation to specific procedures 
with morcellation and in relation to preselection for the 
following two settings: the MIS unit versus the gyneco-
logic oncology unit and abdominal surgery versus MIS. 
Finally, the incidence of occult LMS was compared be-
tween MIS and traditional approach cases in a tertiary 
teaching hospital.
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MATERIAL AND METHODS
Design and patients
This was a retrospective observational study performed 
on datasets gathered in a tertiary referral and teaching cent-
er, in the Department of Gynecology and Oncology and the 
Department of Pathomorphology at Jagiellonian University, 
Cracow, Poland. Data collection began after the approval 
of the Jagiellonian University-Medical College Institutional 
Review Board (No 122.6120.42.2017). Firstly, the Department 
of Pathomorphology digital archives were searched for the 
pathological diagnosis of “leiomyosarcoma”. The specimen 
provider was limited to the Department of Gynecology 
and Oncology, and the search was limited to the period 
between January 1, 2010 and December 31, 2016. The in-
clusion criterion was uterine LMS. At the same time, all 
surgical procedures performed for presumed fibroids were 
registered to establish the prevalence of LMS in the study 
population and the risk of LMS morcellation during surgeries 
performed for presumed fibroids. Records were classified 
with respect to the surgical approach-abdominal surgery 
versus MIS (laparoscopy and other vaginal procedures, in-
cluding hysteroscopy). Moreover, procedures were divided 
into myomectomy and hysterectomy, and laparoscopic pro-
cedures with the use of power morcellation were counted. 
All consecutive patients undergoing surgery for presumed 
myomas were included in the study. Medical, pathological 
and surgical reports were reviewed to confirm indications, 
procedures and pathological diagnoses.
Subsequently, medical records (traditional and digital) of 
women diagnosed with LMS were systematically reviewed 
in terms of clinical characteristics and surgical approach. 
The data on patient demographics (age, body mass index, 
gravidity and parity, hormonal status, medical past history 
of malignancies and surgeries), reported symptoms, ultra-
sound findings (number of uterine masses and diameter of 
the largest mass), possible endometrial histopathological 
verification, surgical management (type of primary sur-
gery, use of minimally invasive techniques, application of 
high-power morcellation) and, finally, tumor characteristics 
(grade and stage) were retrieved from clinical dossiers, ul-
trasound printouts and pathological reports. This parallel 
record search methodology (‘LMS’, surgery of ‘presumed 
myomas’) was designed to estimate the incidence of occult 
LMS in presumed myoma surgeries and the proportion of 
occult LMS to preoperatively recognized LMS cases.
Settings 
During the study period, the Department of Gynecology 
and Oncology consisted of two surgical units, Gynecologic 
Oncology and Endoscopic Gynecology (or MIS unit), in ad-
dition to Chemotherapy and Brachytherapy units. The two 
surgical units with two operating theatres performed the sur-
gical treatment of selected female populations. The gyneco-
logic oncology unit was targeted for the treatment of patients 
with cancer, especially when extended abdominal surgery 
was planned or contraindications to MIS were present. 
Patient management 
An attending obstetrician-gynecologist or gynecolo-
gist-oncologist (more than 15 doctors in the study period) 
conducted qualifications for surgery. The gynecological 
examination, including vaginal speculum and bimanual 
examination, transvaginal sonography and colposcopy, and 
3D sonohysterography (when needed) [8], and detailed 
counseling were performed. All women had a Pap smear 
test done no earlier than one year prior to surgery. All opera-
tions were performed by attendings or residents under the 
supervision of a participating attending physician. 
Statistical analysis
The incidence of occult LMS during myoma surgery and 
data for other important endpoints (power morcellation, 
laparoscopy, laparoscopic and abdominal myomectomy) is 
shown with 95% confidence intervals (CIs) using the Wilson 
method recommended for use with a small n [9]. The relative 
risk (RR) of occult LMS in MIS cases and the 95% CI [10] were 
calculated [11]. Using the test of significance, the P-value 
was calculated [12]. Statistical significance was defined as 
P ≤ 0.05. All calculations were performed using Statistica 
version 10.0 software (StatSoft Inc., Tulsa, OK, USA).
RESULTS
Main findings
Within the seven-year study period (January 2010 to De-
cember 2016), a total of 30,476 patients were hospitalized in 
the included departments, of which 15,348 were subjected 
to surgical treatment in the operating theatres — 7232 
in the gynecologic oncology unit and 8116 in MIS unit; 
2675 cases (mean age ± SD: 47 years ± 9.4, median 46, 
lower-upper quartile: 42–52) underwent surgery for pre-
sumed fibroids — 1712 in the MIS unit and 963 in the 
gynecologic oncology unit. The flow diagram in Figure 1 
shows the specific surgeries and occult LMS incidence. There 
were 6 cases of occult LMS discovered (incidence 1:446; 
0.002; CI 0.0–0.013); one underwent power morcellation 
(incidence 1:951; 0.001; CI 0.0–0.006). 
Proportion of occult LMS to preoperatively 
diagnosed LMS cases
Data from the Department of Pathomorphology re-
vealed 12 cases of LMS — ten uterine and two ovarian. Four 
of the ten (40%) uterine LMS were diagnosed preoperatively, 
whereas six out of ten (60%) were diagnosed postoperatively 
(Fig. 2–4).
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Figure 1. Study flow diagram 
1total and supracervical hysterectomy; 
2hysteroscopic myomectomy, vaginal myomectomy and hysterectomy
0
1
2
3
Preoperatively diagnosed LMSOccult LMS
2010 2011 2012 2013 2014 2015 2016
Figure 2. Proportion of occult to preoperatively diagnosed LMS by 
the year of recognition
Preselection for MIS 
and Gynecologic Oncology units
Comparative assessment of the two units (MIS vs. Gy-
necologic Oncology) was made in terms of the proportion of 
procedures with high-power morcellation (Fig. 5). During the 
study period, 789 procedures with high-power morcellation 
(476 LSH, 313 laparoscopic myomectomies) were performed 
Figure 3. Presumed subserosal myoma in transvaginal ultrasound, 
which proved to be leiomyosarcoma in histopatologic examination
in the MIS unit, and no LMS was morcellated. Over the same 
time period, 162 high-power morcellations (111 LSH, 51 lapa-
roscopic myomectomies) were carried out in the Gynecologic 
Oncology unit, where one case of LMS was morcellated during 
laparoscopic myomectomy (ratio of LMS morcellation, 1:162, 
0.006, CI 0.001–0.034; ratio of LMS morcellation on laparo-
scopic myomectomy, 1:51, 0.02, CI 0.0035–0.1). 
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Myomectomy in reproductive age
Among 872 women who underwent myomectomy 
(mean age ± SD: 37 years ± 7.6, median 37, lower-upper 
quartile: 32–42), 793 (91%) were performed in women of 
reproductive age (< 45 years). There was 1 case of LMS 
(1:793, 0.001; CI 0.0–0.007).
Case series of LMS: characteristic and 
surveillance 
The demographic and clinical data for women with LMS, 
both occult and preoperatively diagnosed cases, is shown 
in Table 1. Uterine LMS was morcellated by laparoscopic 
high-power morcellation during laparoscopic myomectomy 
in one 62-year-old woman. Apparently, no history of abnor-
Figure 4. Uterus with presumed myoma. (A) Grey scale ultrasound, 
and (B) power Doppler. There are not highly specific features of 
leyomyosarcoma, which allow to accurate discrimination between 
myoma and LMS. Finaly, LMS was recognized after surgery 
U — uterus; E — endometrium; L — presumed myoma/LMS
Figure 5. Myoma surgery and morcellation
0
450
900
1350
1800
Onco UnitMIS Unit
Power MorcellationMyoma surgery
1712
963
789
162
Abdominal vs. MIS surgery 
The incidence of occult LMS was 1:1178 (0.001; CI 0.0–
0.005) during MIS procedures and 1:1008 (0.001; CI 0.0–
0.006) during laparoscopic procedures. Among 383 women 
treated by laparoscopic myomectomy, 364 underwent 
high-power morcellation (95%; Fig. 1). Within this group, 
the one and only case of morcellated LMS was identified. No 
LMS was identified in patients from the LSH or hysteroscopic 
myomectomy groups.
The incidence of operating on occult LMS during tradi-
tional surgery was calculated and compared to the frequen-
cy during MIS. Five occult LMS cases were encountered on 
laparotomy. Given that the number of traditional approach 
procedures was 1497, the estimated ratio for operating on 
occult LMS was 1:299 (0.003; CI 0.0–0.015). This result, com-
pared with the incidence calculated for MIS, represented 
a four-fold higher risk of occult LMS in traditional approach 
surgeries, but did not reach statistical significance (RR 3.9; 
CI 0.46–33.6, P = 0.2).
Figure 6. Surgical specimen of morcellated uterine leiomyosarcoma 
(left) and metastatic sarcoma of the greter omentum representing 
uterine leiomyosarcoma recurrence (right). Hematoxylin-eosin 
staining, (top row) 20x and (bottom row) 40x magnification. 
First circle  — there are significant nuclear polymorphism (short arrows) 
and atypia of spindle tumor cells. Second circle — the number of 
mitotic figures reaches 14 on 10 high power fields (HPF) of view (40×) 
and the one is marked by the long arrow. Third circle — hypercellularity 
and nuclear atypia (arrows) and fourth circle — interlacing fascicles of 
spindle cells (marked with a dashed line), indicate malignancy
A
B
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mal uterine bleeding, anemia, or bladder dysfunction was 
found in her medical records, and laparoscopic myomectomy 
was strongly preferred by patient to hysterectomy, as well 
as to the lack of treatment. Interestingly, the patient had al-
ready undergone conservative myomectomy 7 years earlier. 
The patient did not receive further treatment in our depart-
ment, but was operated on in the general surgery ward of 
University Hospital 5 years after laparoscopy for abdominal 
tumor. Metastatic LMS of the greater omentum was con-
firmed histopathologically nearly 5 years after laparoscopic 
high-power morcellation (Fig. 6). As for other patients with 
occult LMS, one 19-year-old woman underwent abdominal 
myomectomy, and four postmenopausal patients underwent 
total abdominal hysterectomy as primary treatment. 
Three women, aged 79, 54 and 62 years, were diagnosed 
with LMS on dilatation and curettage performed because of 
abnormal uterine bleeding/irregular heavy menstrual bleed-
ing complicated by anemia. One 81-year-old woman was 
diagnosed by cervical biopsy.
DISCUSSION
The current study found that occult LMS occurred in 
1:446 surgeries in women with presumed myomas, and 
more than half of all LMS cases recognized during the same 
period were occult. The incidence of LMS morcellation dur-
ing laparoscopy was 1:951 procedures. The prevalence of 
occult LMS was higher in traditional abdominal procedures 
(1:299). Among the six women with occult LMS, five were 
peri- or postmenopausal, whereas one was a very young 
woman of reproductive age. Detailed analysis of abdominal 
versus MIS surgery and the Gynecologic Oncology unit versus 
the MIS unit indicated that an important factor influencing 
the rate of occult LMS was the preselection of patients with 
presumed myomas to abdominal surgery or MIS procedures, 
which could have minimized the rate of LMS morcellation. 
The results show that the use of morcellation for all suspected 
myomas may introduce a level of risk similar to both FDA 
calculations; 1:498 [4] and 1:495 to 1:1100 [13] of occult LMS. 
Paradoxically, in the MIS unit, with a significantly higher rate of 
power morcellation, the risk of encountering occult LMS was 
lower than in the gynecologic oncology unit due to the differ-
ent prevalences of LMS (0:1712 vs 6:963, respectively). Thus, 
selection of specific centers and units (such as Gynecologic 
Oncology units) can overestimate the prevalence due to the 
higher-risk population treated. On the other hand, selected 
reports from only laparoscopic procedures or from only MIS 
centers may indicate a lower prevalence of occult LMS or risk 
of power morcellation [14–16] than multicenter studies [17].
The main limitations of this study are its retrospective 
nature and the single tertiary center study design. Strengths 
of the study include (i) analysis of data relative to all surgeries 
for presumed myomas during the study period, (ii) parallel 
analysis of the incidence of LMS recognized and treated 
during the study period, (iii) analysis was performed on data 
from the period, reflecting the current general (medium) 
quality of preoperative diagnostics (typical variability be-
tween different doctors, ultrasound machines and proce-
dures), and (iv) the lack of influence of the FDA statement on 
the decision-making processes in the center (lack of specific 
time-dependent changes in diagnostics and procedures).
If our study design was based on a single MIS unit or 
MIS procedures only, we would have found no occult LMS 
cases as well as no occult LMS in women of reproductive 
age. Indeed, a recent case series of laparoscopic myomec-
tomies in women of reproductive age reported no cases of 
LMS morcellation [16]. Based on these results and a recently 
suggested algorithm [18] for the use of power morcellation, 
one can suppose that morcellation in young women is very 
safe. In our series, abdominal myomectomy was performed 
in very young woman without suspicion of LMS. However, 
9 of 10 women with LMS were peri- or postmenopausal and 
over 50 years of age. The FDA emphasizes [13] that sarcomas 
in women undergoing surgeries due to presumed myomas 
approaches 2–3% in those over 60 years [19–21]. It should 
be highlighted that leyomyosarcomas often are unidentified 
before surgery as showed the data from the Cancer Registry 
of Norway [22], and in the Norwegian cohort, power morcel-
lation of LMS has not led to reduced survival. In our study the 
woman with LMS who underwent power morcellation is 1 of 
3 women with the longest survival after LMS recognition from 
the case series. However, several new studies included in the 
recent FDA review [13] provide some evidence supporting 
an increased risk of relapse and decreased overall survival 
after power morcellation of LMS [19, 23, 24]. Conversely, an-
other interpretation of the available data suggests that even 
intact removal of LMS has no advantage for mortality rate 
compared with power or any other type of morcellation [25]. 
Probably other multiple factors are more pivotal for patient 
survival than incidence of power morcellation.
The main implication of the current study is that the sim-
ple selection of patients through gynecological examination 
and ultrasonography may significantly change the prevalence 
of occult LMS and affect the risk associated with power mor-
cellation. The incidence of occult LMS may be very low in MIS 
centers after appropriate preselection without significant risk 
of power morcellation. The FDA position after a recent review 
of the literature is the same as the previous [13], and power 
morcellators are contraindicated for removal of myomas in the 
majority of cases. From our European perspective, it is pivotal 
that well-balanced European Guidelines be developed by the 
main professional societies, considering advantages and dis-
andvatages of these procedures in specific groups of women. 
On the other hand, there is reasonable question whether 
morcellation of occult LMS is more risky than the delay 
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of treatment by alternative therapies without histologi-
cal examination (ie. magnetic-resonance-guided focused 
ultrasound surgery, uterine artery embolization) including 
pharmaceutical therapy (ie. ulipristal acetate) [6, 26].
Nowadays, studies should focus on improving the 
diagnostic accuracy and safety of myoma management. 
Probably the best way to obtain a true estimation of the 
incidence of LMS in presumed myoma cases and the morcel-
lation rate of LMS is by performing a prospective registered 
multicenter study and maintaining an obligatory national 
registry of such events, as well as by reporting occult LMS 
cases that were unrecognized via histology before surgery 
for uterine tumors described as presumed myomas.
CONCLUSIONS
Selection of patients based on gynecological and ul-
trasound examinations may affect the prevalence of occult 
LMS in women with presumed myomas undergoing surgery 
and lower the risk of LMS morcellation. All women, even the 
very young, should be informed about the risk of occult LMS 
when the use of power morcellators or other conservative 
therapies are being considered, especially when histological 
examination is not being performed.
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